Advertisement · 728 × 90

Posts by Daniel Kim

Post image

Super excited to share our latest work on RNA liquid biopsy via nanopore sequencing for novel biomarker discovery and cancer early detection!

www.biorxiv.org/content/10.1...

9 months ago 8 4 2 0

RNA liquid biopsy via nanopore sequencing for novel biomarker discovery and cancer early detection www.biorxiv.org/content/10.1101/2025.07....

9 months ago 2 1 0 0

RNA liquid biopsy via nanopore sequencing for novel biomarker discovery and cancer early detection www.biorxiv.org/content/10.1101/2025.07....

9 months ago 2 1 0 0

A huge thank you to the American Cancer Society @americancancersoc.bsky.social for funding this work in our lab through a Research Scholar award!

9 months ago 0 0 0 0

This work was spearheaded by two amazing grad students, co-first authors Vikas Peddu & Alex Hill, with significant contributions from Sreelakshmi Velandi Maroli & Connor Mattingly, as well as our wonderful collaborators Joshua Gardner, Karen Miga, and Rebecca Fitzgerald!

9 months ago 1 0 1 0

Our study highlights the utility of our long-read sequencing-based RNA liquid biopsy approach for discovering and targeting early stages of disease with molecular precision.

9 months ago 0 0 1 0

Through our LOCATE-seq RNA liquid biopsy platform technology, we also discovered potential therapeutic targets, including metabolic, signaling, and immune checkpoint pathways, that are highly upregulated in both precancer and cancer patients.

9 months ago 0 0 1 0

Using these novel, unannotated cell-free RNAs, we built a custom transcriptome reference for quantification, feature selection, and machine learning to accurately classify both precancerous Barrett's esophagus with high-grade dysplasia and early-stage esophageal adenocarcinoma.

9 months ago 1 0 1 0

We leveraged the power of single-molecule, long-read sequencing of cell-free RNA using Oxford Nanopore Technologies' PromethION platform @nanoporetech.com to discover over 270,000 novel, intergenic cell-free RNAs.

9 months ago 0 0 1 0
Advertisement
Post image

Super excited to share our latest work on RNA liquid biopsy via nanopore sequencing for novel biomarker discovery and cancer early detection!

www.biorxiv.org/content/10.1...

9 months ago 8 4 2 0
Small-molecule RNA therapeutics to target prostate cancer Kuzuoglu-Ozturk et al. showcase a therapeutic approach, “translatome therapy,” to combat lethal prostate cancer. Zotatifin, a clinical molecule, targets the RNA-helicase eIF4A. Zotatifin decreases the select translation of key oncogenes, androgen receptor (AR), and HIF1α through remodeling their 5′ UTR RNA structure. Zotatifin enhances anti-androgen and radiotherapy sensitivity, highlighting a promising anti-cancer treatment.

Happy to share our new work with @haognguyen on targeting mRNA translation of oncogenes by RNA structure remodeling with a small molecule zotatifin. Congrats to ⁦@DuyguKuzuoglu⁩ an amazing postdoc and all the authors and collaborators!

cell.com/cancer-cell/fu…

1 year ago 9 4 1 0
Post image

Register today for RNA 2025 - the 30th Annual Meeting of the RNA Society! This year’s meeting will be held at the beautiful Town and Country Resort & Convention Center in sunny San Diego, California, USA from May 27 - June 1.
www2.rnasociety.org

1 year ago 8 6 2 0
Post image

We are pleased to announce registration for RNA 2025 - the 30th Annual Meeting of the RNA Society - is now open!
www2.rnasociety.org

This year’s meeting will be held at the beautiful Town and Country Resort & Convention Center in sunny San Diego, California, USA from May 27th - June 1st, 2025.

1 year ago 41 24 1 4